

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 24, 2008

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On July 24, 2008, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for the fiscal quarter ending June 30, 2008. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (GAAP), as follows:

- Revenues. We present international and total company revenue growth rates at constant foreign exchange rates. We believe that presenting revenue growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
- Operating Income. We present BD's operating income, both alone and as a percentage of revenues, for the third quarter of fiscal year 2007 after excluding the impact of the in-process research and development ("R&D") charge relating to our acquisition of Plasso Technology, Ltd. ("Plasso"). We also present BD's operating income, both alone and as a percentage of revenues, for the first nine months of fiscal year 2007 after excluding the impact of the in-process R&D charges relating to our acquisition of Plasso and our acquisition of TriPath Imaging, Inc. ("TriPath"). These charges affected reported operating income for the periods presented, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of BD's underlying performance, and allow investors to better understand BD's comparative operating performance for the periods presented.
- Effective Tax Rate. We present BD's effective tax rate for the third quarter of fiscal year 2007 after excluding the impact of the in-process R&D charges relating to our acquisition of Plasso. We also present BD's effective tax rate for the first nine months of fiscal year 2007 after excluding the impact of the in-process R&D charges relating to our acquisition of TriPath and Plasso. These charges, which are not considered part of ordinary operations by management and are not tax deductible, caused our effective tax rate for such periods to be higher than it otherwise would have been. Management believes that these adjusted measures of our effective tax rate are more indicative of BD's underlying results, and allow investors to better understand BD's comparative effective tax rate for such periods.
- Income from Continuing Operations. We present BD's income from continuing operations, both alone and as a percentage of revenues, for the third quarter of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to our acquisition of Plasso. We also present BD's income from continuing operations, both alone and as a percentage of revenues, for the first nine months of fiscal year 2007 after excluding the impact of the in-process R&D charges relating to our acquisition of TriPath and Plasso. These charges affected reported income from continuing operations for the periods presented, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD's underlying performance, and allow investors to better understand BD's comparative income from continuing operations for such periods.
- Earnings Per Share. We present BD's earnings per share from continuing operations for the third quarter of fiscal year 2007 after excluding the impact of the in-process R&D charge relating to our acquisition of Plasso. We also present earnings per share from continuing operations for the first nine months of fiscal year 2007 and for the full 2007 fiscal year after excluding the impact of the in-process R&D charges relating to our acquisition of TriPath and Plasso. These charges caused reported earnings per share for such periods to be lower than they otherwise would have been, although these charges are not considered by management to be part of ordinary operations. We believe that measures of earnings per share that are adjusted for the impact of these charges are more indicative of BD's underlying performance and allow investors to more easily compare BD's results for the periods presented to other periods.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated July 24, 2008, which is furnished pursuant to Item 2.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: July 24, 2008

INDEX TO EXHIBITS

Exhibit
Number

Description of Exhibits

99.1

Press release dated July 24, 2008, which is furnished pursuant to Item 2.02.

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR THIRD FISCAL QUARTER

Franklin Lakes, NJ (July 24, 2008) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.868 billion for the third fiscal quarter ended June 30, 2008, representing an increase of 14.5 percent over the prior year period. This quarter's revenue growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for nearly 7 percentage points of the increase in quarterly revenues.

"We are pleased that all segments and regions, particularly Europe and Asia, contributed to solid revenue growth," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "We are also pleased with our operating results, which in part, have enabled us to raise our earnings guidance once again despite continued pressure from increasing raw material costs."

Analyses of Third Quarter and Nine-Month Periods of Fiscal Year 2008 and 2007 Earnings

Reported diluted earnings per share from continuing operations were \$1.18 for the third quarter of fiscal 2008 and 95 cents for the third quarter of fiscal 2007. For the nine-month period ending June 30, 2008, reported diluted earnings per share from continuing operations were \$3.34. For the nine-

month period ending June 30, 2007, reported diluted earnings per share from continuing operations were \$2.38.

The following analysis (Table 1) of diluted earnings per share from continuing operations for the three-month and nine-month periods ended June 30, 2008 and 2007, identifies the specified items that affect comparability of results between periods. As illustrated, diluted earnings per share from continuing operations of \$1.18 for the third fiscal quarter of 2008 increased by 20 percent over diluted earnings per share from continuing operations, excluding the specified item, of 98 cents for the third fiscal quarter of 2007. For the nine-month periods, diluted earnings per share from continuing operations of \$3.34 for fiscal 2008 increased by 17 percent over comparable fiscal 2007 diluted earnings per share from continuing operations of \$2.86, which exclude the specified items.

(Table 1)	Three Months Ended June 30,			Nine Months Ended June 30,		
	FY2008	FY2007	% Change	FY2008	FY2007	% Change
Diluted EPS from Continuing Operations:	\$ 1.18	\$ 0.95	24%	\$ 3.34	\$ 2.38	40%
Specified Items:						
In-Process Research and Development Charge	-	0.03 (1)		-	0.48 (2)	
Diluted EPS from Continuing Operations						
Excluding Specified Items:	<u>\$ 1.18</u>	<u>\$ 0.98</u>	<u>20%</u>	<u>\$ 3.34</u>	<u>\$ 2.86</u>	<u>17%</u>

- (1) Represents the effect on diluted earnings per share from continuing operations of the in-process research and development (“IPR&D”) charge recorded in the third quarter of fiscal 2007 related to the Plasso Technology acquisition.
- (2) Represents the effect on diluted earnings per share from continuing operations of the IPR&D charges recorded in the third and first quarters of fiscal 2007 related to the Plasso and TriPath acquisitions, respectively.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$1.016 billion, representing an increase of 15 percent from the prior year period. Pharmaceutical Systems and Diabetes Care products

led revenue growth in the segment. For the nine-month period ended June 30, 2008, the BD Medical segment reported 12 percent revenue growth.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$553 million, representing an increase of 13 percent from the prior year's quarter. Sales of safety-engineered devices, TriPath products and infectious disease testing systems contributed to revenue growth. For the nine-month period ended June 30, 2008, the BD Diagnostics segment reported 14 percent revenue growth.

In the BD Biosciences segment, worldwide revenues for the quarter were \$298 million, representing an increase of 16 percent from the prior year's quarter. Demand for clinical and research instruments and reagents were the primary growth drivers. For the nine-month period ended June 30, 2008, the BD Biosciences segment reported 16 percent revenue growth.

Geographic Results

Third quarter revenues in the U.S. were \$798 million, representing an increase of 4 percent over the prior year period. Revenues outside the U.S. were \$1.069 billion, representing an increase of 24 percent over the prior year period, with approximately 13 percentage points of the increase resulting from the favorable impact of foreign currency translation.

For the nine-month period ended June 30, 2008, revenues in the U.S. were \$2.372 billion, representing an increase of 6 percent over the prior year period. Revenues outside of the U.S. were \$2.948 billion, representing an increase of 20 percent over the prior year period, with approximately 11 percentage points of the increase resulting from the favorable impact from foreign currency translation.

Fiscal 2008 Outlook for Full Year

The Company raised its guidance for full fiscal year 2008 diluted earnings per share from continuing operations to approximately 16 percent from approximately 13 to 14 percent over adjusted diluted earnings per share from continuing operations of \$3.84 for the full fiscal year 2007. Reported diluted earnings per share from continuing operations for the full fiscal year 2007 were \$3.36, which included 48 cents for in-process research and development charges related to the TriPath and Plaso acquisitions. Excluding these charges, adjusted diluted earnings per share from continuing operations for the full fiscal year 2007 were \$3.84.

Conference Call Information

A conference call regarding BD's third fiscal quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (EDT) Thursday, July 24, 2008. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 800-642-1687 (domestic) and 706-645-9291 (international), Conference ID: 52522900, through the close of business on Thursday, July 31, 2008.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2008 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not

limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended June 30,		
	2008	2007	% Change
REVENUES	\$ 1,867,587	\$ 1,631,159	14.5
Cost of products sold	917,362	791,071	16.0
Selling and administrative	440,588	412,164	6.9
Research and development	100,071	92,993	7.6
Acquired in-process research and development	-	7,394	NM
TOTAL OPERATING COSTS AND EXPENSES	1,458,021	1,303,622	11.8
OPERATING INCOME	409,566	327,537	25.0
Interest income	10,956	11,938	(8.2)
Interest expense	(9,017)	(11,598)	(22.3)
Other income, net	(1,285)	1,774	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	410,220	329,651	24.4
Income tax provision	112,811	89,182	26.5
INCOME FROM CONTINUING OPERATIONS	297,409	240,469	23.7
(LOSS)/INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT)/PROVISION OF \$(197) AND \$2,704, RESPECTIVELY	(320)	4,340	NM
NET INCOME	\$ 297,089	\$ 244,809	21.4
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.22	\$ 0.98	24.5
Income from discontinued operations	\$ -	\$ 0.02	NM
Net income	\$ 1.22	\$ 1.00	22.0
Diluted:			
Income from continuing operations	\$ 1.18	\$ 0.95	24.2
Income from discontinued operations	\$ -	\$ 0.02	NM
Net income ⁽¹⁾	\$ 1.18	\$ 0.96	22.9
AVERAGE SHARES OUTSTANDING			
Basic	244,273	244,918	
Diluted	251,648	254,128	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

Three Months Ended June 30,

	2007		
	As Reported	Plasso IPR&D (1)	Excluding Item
Operating Income	\$ 327,537	\$ 7,394	\$ 334,931
as a % of revenues	20.1%		20.5%
Income Taxes	89,182	-	89,182
effective tax rate	27.1%		26.5%
Income from continuing operations	240,469	7,394	247,863
as a % of revenues	14.7%		15.2%
<u>Diluted earnings per share</u>			
Income from continuing operations	\$ 0.95	\$ 0.03	\$ 0.98

(1) Represents the acquired in-process research and development charge of \$7,394 related to the Plasso acquisition.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	Nine Months Ended June 30,		
	2008	2007	% Change
REVENUES	\$ 5,320,279	\$ 4,708,607	13.0
Cost of products sold	2,601,016	2,264,544	14.9
Selling and administrative	1,277,828	1,202,879	6.2
Research and development	287,633	259,620	10.8
Acquired in-process research and development	-	122,133	NM
TOTAL OPERATING COSTS AND EXPENSES	4,166,477	3,849,176	8.2
OPERATING INCOME	1,153,802	859,431	34.3
Interest income	32,489	37,138	(12.5)
Interest expense	(27,455)	(36,152)	(24.1)
Other income, net	252	5,278	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,159,088	865,695	33.9
Income tax provision	315,147	258,636	21.8
INCOME FROM CONTINUING OPERATIONS	843,941	607,059	39.0
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$538 AND \$14,066, RESPECTIVELY	880	23,162	NM
NET INCOME	\$ 844,821	\$ 630,221	34.1
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 3.45	\$ 2.47	39.7
Income from discontinued operations	\$ -	\$ 0.09	NM
Net income (1)	\$ 3.46	\$ 2.57	34.6
Diluted:			
Income from continuing operations	\$ 3.34	\$ 2.38	40.3
Income from discontinued operations	\$ -	\$ 0.09	NM
Net income	\$ 3.34	\$ 2.47	35.2
AVERAGE SHARES OUTSTANDING			
Basic	244,478	245,296	
Diluted	252,944	255,129	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

	Nine Months Ended June 30, 2007			
	As Reported	TriPath IPR&D (1)	Plasso IPR&D (1)	Excluding Items
Operating Income	\$ 859,431	\$ 114,739	\$ 7,394	981,564
as a % of revenues	18.3%			20.8%
Income taxes	258,636	-	-	258,636
effective tax rate	29.9%			26.2%
Income from continuing operations	607,059	114,739	7,394	729,192
as a % of revenues	12.9%			15.5%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 2.38	\$ 0.45	\$ 0.03	\$ 2.86

(1) Represents the acquired in-process research and development charges of \$114,739 and \$7,394 related to the TriPath and Plasso acquisitions, respectively

	Fiscal Year 2007		
	As Reported	IPR&D (2)	Excluding Items
<u>Diluted earnings per share</u>			
Income from continuing operations	\$ 3.36	\$ 0.48	\$ 3.84

(2) Represents the acquired in-process research and development charges related to the TriPath and Plasso acquisitions.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

Three Months Ended June 30,

	2008	2007	% Change
<u>BD MEDICAL</u>			
United States	\$ 401,918	\$ 385,546	4.2
International	614,478	496,440	23.8
TOTAL	\$ 1,016,396	\$ 881,986	15.2
<u>BD DIAGNOSTICS</u>			
United States	\$ 280,118	\$ 272,946	2.6
International	273,304	218,579	25.0
TOTAL	\$ 553,422	\$ 491,525	12.6
<u>BD BIOSCIENCES</u>			
United States	\$ 116,239	\$ 109,593	6.1
International	181,530	148,055	22.6
TOTAL	\$ 297,769	\$ 257,648	15.6
<u>TOTAL REVENUES</u>			
United States	\$ 798,275	\$ 768,085	3.9
International	1,069,312	863,074	23.9
TOTAL	\$ 1,867,587	\$ 1,631,159	14.5

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Nine Months Ended June 30,		
	2008	2007	% Change
<u>BD MEDICAL</u>			
United States	\$ 1,197,689	\$ 1,146,143	4.5
International	1,650,243	1,406,233	17.4
TOTAL	\$ 2,847,932	\$ 2,552,376	11.6
<u>BD DIAGNOSTICS</u>			
United States	\$ 840,695	\$ 781,644	7.6
International	766,050	625,512	22.5
TOTAL	\$ 1,606,745	\$ 1,407,156	14.2
<u>BD BIOSCIENCES</u>			
United States	\$ 333,891	\$ 314,942	6.0
International	531,711	434,133	22.5
TOTAL	\$ 865,602	\$ 749,075	15.6
<u>TOTAL REVENUES</u>			
United States	\$ 2,372,275	\$ 2,242,729	5.8
International	2,948,004	2,465,878	19.6
TOTAL	\$ 5,320,279	\$ 4,708,607	13.0

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States		
	2008	2007	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 243,960	\$ 238,360	2.3
Diabetes Care	102,663	92,116	11.4
Pharmaceutical Systems	49,125	48,692	0.9
Ophthalmic Systems	6,170	6,378	(3.3)
TOTAL	\$ 401,918	\$ 385,546	4.2
BD DIAGNOSTICS			
Preanalytical Systems	\$ 144,416	\$ 139,572	3.5
Diagnostic Systems	135,702	133,374	1.7
TOTAL	\$ 280,118	\$ 272,946	2.6
BD BIOSCIENCES			
Cell Analysis (1)	\$ 80,186	\$ 71,686	11.9
Discovery Labware	36,053	37,907	(4.9)
TOTAL	\$ 116,239	\$ 109,593	6.1
TOTAL UNITED STATES	\$ 798,275	\$ 768,085	3.9

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2008	2007	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 272,064	\$ 233,835	16.3	6.1	10.2
Diabetes Care	97,298	82,754	17.6	4.8	12.8
Pharmaceutical Systems	230,346	168,057	37.1	19.6	17.5
Ophthalmic Systems	14,770	11,794	25.2	12.6	12.6
TOTAL	\$ 614,478	\$ 496,440	23.8	10.6	13.2
BD DIAGNOSTICS					
Preanalytical Systems	\$ 146,345	\$ 121,761	20.2	7.5	12.7
Diagnostic Systems	126,959	96,818	31.1	18.4	12.7
TOTAL	\$ 273,304	\$ 218,579	25.0	12.3	12.7
BD BIOSCIENCES					
Cell Analysis (1)	\$ 141,889	\$ 115,494	22.9	10.4	12.5
Discovery Labware	39,641	32,561	21.7	8.7	13.0
TOTAL	\$ 181,530	\$ 148,055	22.6	10.0	12.6
TOTAL INTERNATIONAL	\$ 1,069,312	\$ 863,074	23.9	10.9	13.0

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	2008	2007	Total		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 516,024	\$ 472,195	9.3	4.2	5.1
Diabetes Care	199,961	174,870	14.3	8.3	6.0
Pharmaceutical Systems	279,471	216,749	28.9	15.4	13.5
Ophthalmic Systems	20,940	18,172	15.2	7.0	8.2
TOTAL	\$ 1,016,396	\$ 881,986	15.2	7.8	7.4
BD DIAGNOSTICS					
Preanalytical Systems	\$ 290,761	\$ 261,333	11.3	5.3	6.0
Diagnostic Systems	262,661	230,192	14.1	8.7	5.4
TOTAL	\$ 553,422	\$ 491,525	12.6	6.9	5.7
BD BIOSCIENCES					
Cell Analysis (1)	\$ 222,075	\$ 187,180	18.6	10.9	7.7
Discovery Labware	75,694	70,468	7.4	1.4	6.0
TOTAL	\$ 297,769	\$ 257,648	15.6	8.3	7.3
TOTAL REVENUES	\$ 1,867,587	\$ 1,631,159	14.5	7.6	6.9

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30,
(Unaudited; Amounts in thousands)

	United States		
	2008	2007	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 729,152	\$ 711,545	2.5
Diabetes Care	298,071	280,255	6.4
Pharmaceutical Systems	151,882	135,961	11.7
Ophthalmic Systems	18,584	18,382	1.1
TOTAL	\$ 1,197,689	\$ 1,146,143	4.5
BD DIAGNOSTICS			
Preanalytical Systems	\$ 428,391	\$ 403,211	6.2
Diagnostic Systems	412,304	378,433	9.0
TOTAL	\$ 840,695	\$ 781,644	7.6
BD BIOSCIENCES			
Cell Analysis (1)	\$ 225,814	\$ 205,237	10.0
Discovery Labware	108,077	109,705	(1.5)
TOTAL	\$ 333,891	\$ 314,942	6.0
TOTAL UNITED STATES	\$ 2,372,275	\$ 2,242,729	5.8

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2008	2007	% Change		
			Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 766,401	\$ 675,741	13.4	3.7	9.7
Diabetes Care	278,736	234,491	18.9	7.1	11.8
Pharmaceutical Systems	563,969	462,540	21.9	8.3	13.6
Ophthalmic Systems	41,137	33,461	22.9	11.6	11.3
TOTAL	\$ 1,650,243	\$ 1,406,233	17.4	6.0	11.4
BD DIAGNOSTICS					
Preanalytical Systems	\$ 408,031	\$ 342,941	19.0	7.5	11.5
Diagnostic Systems	358,019	282,571	26.7	15.8	10.9
TOTAL	\$ 766,050	\$ 625,512	22.5	11.3	11.2
BD BIOSCIENCES					
Cell Analysis (1)	\$ 421,095	\$ 339,146	24.2	13.0	11.2
Discovery Labware	110,616	94,987	16.5	5.4	11.1
TOTAL	\$ 531,711	\$ 434,133	22.5	11.4	11.1
TOTAL INTERNATIONAL	\$ 2,948,004	\$ 2,465,878	19.6	8.3	11.3

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Nine Months Ended June 30, (continued)
(Unaudited; Amounts in thousands)

			Total		
	2008	2007	Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 1,495,553	\$ 1,387,286	7.8	3.1	4.7
Diabetes Care	576,807	514,746	12.1	6.7	5.4
Pharmaceutical Systems	715,851	598,501	19.6	9.0	10.6
Ophthalmic Systems	59,721	51,843	15.2	7.9	7.3
TOTAL	\$ 2,847,932	\$ 2,552,376	11.6	5.3	6.3
BD DIAGNOSTICS					
Preanalytical Systems	\$ 836,422	\$ 746,152	12.1	6.8	5.3
Diagnostic Systems	770,323	661,004	16.5	11.9	4.6
TOTAL	\$ 1,606,745	\$ 1,407,156	14.2	9.2	5.0
BD BIOSCIENCES					
Cell Analysis (1)	\$ 646,909	\$ 544,383	18.8	11.9	6.9
Discovery Labware	218,693	204,692	6.8	1.7	5.1
TOTAL	\$ 865,602	\$ 749,075	15.6	9.1	6.5
TOTAL REVENUES	\$ 5,320,279	\$ 4,708,607	13.0	7.1	5.9

(1) Cell Analysis consists of the Immunocytometry Systems and the Pharmingen units that were previously reported separately.